Herceptin, also known by its generic name trastuzumab, is a targeted therapy used primarily in the treatment of HER2-positive breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some cancer cells. By targeting HER2, Herceptin inhibits the proliferation of these cancerous cells.
